Chemosensitivity of Uterine Cervical Cancer Demonstrated by the Histoculture Drug Response Assay

Lee, Shin-Wha; Kim, Yong‐Man; Kim, Moon-Bo; Kim, Dae-Yeon; Kim, Jong-Hyeok; Nam, Joo‐Hyun; Kim, Young‐Tak

doi:10.1620/tjem.219.277

Cited by 14 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Topotecan is currently approved for use in the United States as second-line therapy for pretreated ovarian and small-cell lung cancer, while irinotecan is the treatment of choice when used in combination with fluoropyrimidines as first-line therapy for patients with advanced colorectal cancer or as single agent after failure of 5-FU-based CT [101]. Despite that belotecan showed in vitro activity against CC cells comparable to that of platinum compounds and topotecan [102], a Phase I study in 16 patients with ACC showed no clinical responses, although median OS was 12.3 months [103], which is within the expected time with current cisplatin doublets. Exatecan has shown 6-and 28-fold greater cytotoxicity against a panel of 32 malignant cell lines as compared with irinotecan and topotecan, respectively [104].…”

Section: Belotecan and Exatecanmentioning

confidence: 99%

Emerging drugs for the treatment of cervical cancer

Serrano-Olvera

Cetina

Coronel

et al. 2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Concurrent cisplatin with radiation and lately, gemcitabine-cisplatin chemoradiation has resulted in small but significant improvements in the treatment of locally advanced and high-risk early-stage patients. So far, only antiangiogenic therapy with bevacizumab added to cisplatin chemoradiation has demonstrated safety and encouraging results in a Phase II study. In advanced disease, cisplatin doublets yield median survival rates not exceeding 14 months. The first Phase III study of bevacizumab, added to standard chemotherapy cisplatin- or non-cisplatin-containing doublet, has shown significant increase in both overall survival and progression-free survival. Further studies are needed before bevacizumab plus chemotherapy can be considered the standard of care for advanced disease. The characterization of the mutational landscape of CC and developments of novel targeted therapies may result in more effective and individualized treatments for CC. The potential efficacy of knocking down the key alterations in CC, E6 and E7 human papilloma virus oncoproteins must not be overlooked.

show abstract

Section: Belotecan and Exatecanmentioning

confidence: 99%

Emerging drugs for the treatment of cervical cancer

Serrano-Olvera

Cetina

Coronel

et al. 2015

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

show abstract

“…Although the incidence and the mortality of cervical cancer have significantly declined, cervical cancer is still a leading cause of cancer-related death in women (Lee et al, 2009). New prophylactic HPV (human papillomavirus) vaccines can prevent infections by a subset of these HPVs, but will not eliminate pre-existing HPV infections, new infections by high-risk HPVs not targeted by the vaccines, or cervical cancers and precancerous lesions that arise from these HPV infections (Roden and Wu, 2006).…”

Section: Introductionmentioning

confidence: 99%

Standardized flavonoid-rich fraction of Artemisia princeps Pampanini cv. Sajabal induces apoptosis via mitochondrial pathway in human cervical cancer HeLa cells

Lee

Chung

et al. 2012

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…Squamous cell carcinoma of the cervix (SCC) is the most common malignant tumor of the female genital tract and also a leading cause of cancer-related death in the female population worldwide [10]. The main biological behavior of cervical carcinoma includes local invasion and lymph node metastasis.…”

Section: Introductionmentioning

confidence: 99%

Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix

2010

Med Oncol

View full text Add to dashboard Cite

To investigate the significance of PRL-3 expression in progression and metastasis of squamous cell carcinoma of the cervix (SCC). PRL-3 expression was detected by immunohistochemistry in 22 normal cervical epithelia, 30 moderate-severe dysplasia (CIN II-III) and 90 SCC cases. A total of 28 patients with SCC had lymph node metastasis, and PRL-3 expression of metastatic lymph node was detected. The association between PRL-3 expression and various clinical pathological variables in 90 patients with SCC was analyzed. Expression of PRL-3 in SCC was higher than that in normal and CINII-III, as well as higher in CINII-III than in normal (P<0.05 in all instances). PRL-3 expression was significantly different between different tumor sizes, lymph-vascular space invasion status and lymph node metastasis status (P<0.05 in all instances). PRL-3 expression in lymph node metastasis was significantly higher than that in primary SCC (P=0.049). In lymph node metastasis, the frequency of staining in cytoplasm predominantly was higher than that in matched primary cancers (P=0.001). PRL-3 may be involved in carcinogenesis of cervix and lymph node metastases of SCC and serves as an unfavorable prognostic factor in patients with SCC. PRL-3 localization in plasma may be related with cancer progress and metastasis.

show abstract

Chemosensitivity of Uterine Cervical Cancer Demonstrated by the Histoculture Drug Response Assay

Cited by 14 publications

References 19 publications

Emerging drugs for the treatment of cervical cancer

Emerging drugs for the treatment of cervical cancer

Standardized flavonoid-rich fraction of Artemisia princeps Pampanini cv. Sajabal induces apoptosis via mitochondrial pathway in human cervical cancer HeLa cells

Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix

Contact Info

Product

Resources

About